All companies
Visit website
REXIS BIOTECH, INC.
OperatingRexis Biotech Inc.
Food · Founded 2022
Making drinks taste better, your medicine work better & your drugs more fun
Post-money valuation ⓘ
$12.5M
As of Apr 2024 · from REXIS BIOTECH, INC. Preferred Stock 1 · pre-money + amount raised, not a traded price
Total raised
$469,889
Across 1 round since 2023
Latest share price
$1.25
REXIS BIOTECH, INC. Preferred Stock 1 offering price
Financials
FY2021–FY2022 · from SEC filings · hover any figure for its source$3.1M
$141K
2021
$8.4M
$894K
2022
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2021
FY2022
Income statement
Revenue
$3,119,575
$8,400,823
Cost of goods sold
$1,293,815
$3,429,923
Gross margin
59%
59%
Net income
$140,884
$893,891
Taxes paid
$33,201
$0
Balance sheet
Cash
$48,195
-$121,220
Accounts receivable
$112,646
$4,565,035
Total assets
$2,509,831
$8,262,782
Short-term debt
$0
$0
Long-term debt
$0
$469,797
Total liabilities
$0
$469,797
Other
Headcount
—
22
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$12.5M
post-money
REXIS BIOTECH, INC. Preferred Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $469.9K / $1.2MInvestors 214Post-money $12.5M
Reg CF annual-report compliance
Not requiredFewer than 300 holders of record
Filed 1 of 3 annual reports (FY2023–FY2025)
214 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0002000970Share price $1.25
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.